Results 1 to 10 of about 16,492 (195)

Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review [PDF]

Frontiers in Cardiovascular Medicine, 2022
The function of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a novel plasma protein, has mainly been involved in cholesterol metabolism in the liver, while, more interestingly, recent data have shown that PCSK9 also took part in the modulation ...
Na-Qiong Wu, Jian-Jun Li, Wu Na-Qiong
exaly   +5 more sources

Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis

Biomedicines, 2023
Despite being the most common treatment strategy in the management of atherosclerosis and subsequent cardiovascular disease, classical statin therapy has certain disadvantages, including numerous side effects.
Anastasia V. Poznyak, Vasily N. Sukhorukov, Ilya I. Eremin, Irina I. Nadelyaeva, Nikita A. Gutyrchik, Alexander N. Orekhov   +5 more
doaj   +3 more sources

Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome

The Turkish Journal of Gastroenterology
Objectives: This study aimed to investigate the potential roles of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and apelin in the etiology of fibromyalgia syndrome (FS).
Nevsun Pihtili Taş, Rabia Aydogan Baykara, Ayhan Kamanli, Ali Gürbüz, Erkan Cure, Medine Cumhur Cüre, Mehmet Erdem, Tugce Tasar Yildirim   +7 more
doaj   +3 more sources

A molecular modeling approach for structure-based virtual screening and identification of novel anti-hypercholesterolemic agents from Grape

Informatics in Medicine Unlocked, 2022
Hypercholesterolemia is a potential cardiovascular hazard that requires immediate therapeutic intervention. Research has shown that 3-Hydroxy-3-methylglutaryl- CoA reductase (HMG CoA reductase) and Proprotein convertase subtilisin/kexin type 9 (PCSK9 ...
Precious A. Akinnusi, Samuel O. Olubode, Adebowale A. Alade, Samad A. Ahmed, Susan F. Ayekolu, Taiwo M. Ogunlade, Damilola J. Gbore, Olayemi D. Rotimi, Abigail O. Ayodele   +8 more
doaj   +1 more source

Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report

Journal of Medical Case Reports, 2023
Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/
Tanawan Kongmalai, Nalinee Chuanchaiyakul, Yuttana Srinoulprasert, Nuntakorn Thongtang   +3 more
doaj   +1 more source

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9 [PDF]

Pharmacological Reviews, 2017
The secretory proprotein convertase (PC) family comprises nine members, as follows: PC1/3, PC2, furin, PC4, PC5/6, paired basic amino acid cleaving enzyme 4, PC7, subtilisin kexin isozyme 1/site 1 protease (SKI-1/S1P), and PC subtilisin/kexin type 9 (PCSK9).
Nabil G, Seidah, Marianne, Abifadel, Stefan, Prost, Catherine, Boileau, Annik, Prat   +4 more
openaire   +2 more sources

Proprotein Convertase Subtilisin Kexin 9 Inhibitors [PDF]

Cardiology Clinics, 2018
High levels of low-density lipoprotein cholesterol (LDL-C) are directly associated with an increased risk of cardiovascular disease. Reducing LDL-C levels reduces the incidence of cardiovascular events. Several lipid-lowering approaches are available to achieve the LDL-C levels recommended by current guidelines, statins being the first-line therapy ...
Angela, Pirillo, Alberico Luigi, Catapano   +1 more
openaire   +2 more sources

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors [PDF]

Clinical Research in Cardiology Supplements, 2019
Lipoprotein(a) (Lp(a)) is an internationally accepted independent atherogenic risk factor. Details about its synthesis, many aspects of composition and clearance from the bloodstream are still unknown. LDL receptor (LDLR) (and probably other receptors) play a role in the elimination of Lp(a) particles.
Julius, U, Tselmin, S, Schatz, U, Fischer, S, Bornstein, S R   +4 more
openaire   +2 more sources

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors [PDF]

Canadian Medical Association Journal, 2019
PCSK9 is a protease that degrades hepatic LDL-C receptors. Evolocumab and alirocumab are fully human monoclonal antibodies administered as subcutaneous injections that inhibit PCSK9, preserving receptor availability to clear circulating LDL-C.[1][1],[2][2] In randomized, placebo-controlled ...
Derek, Leong, Peter E, Wu
openaire   +2 more sources